Yousuf Zafar

RT @ASCO: For #ASCODailyNews, @yzafar breaks down how technology & data can lower #cancercare costs, reduce acute care utilization, & strea…

LOVE this: "Looking for an actually concise explanation of a half-century’s worth of research and arguments about health care spending in the U.S.?" Well, here it is in one ppt. Thanks, @bobjherman @statnews https://t.co/tEaBft6blu cc: @DusetzinaS @StephWheelerUNC https://t.co/9vv5buEHBJ

RT @fumikochino: Scientists NEED to become better communicators. Proud of this manuscript highlighting HOW to present your research to div…

Deciding between adjuvant therapy yes/no for stage II #coloncancer? Check out @gabe_a_brooks great summary. I would only add this: patient preference plays a role, of course #ASCO22

Gabriel Brooks @gabe_a_brooks

My preliminary takeaways re: DYNAMIC: In stage 2 colon cancer, only three biomarkers are ultimately useful for selecting adjuvant therapy candidates after R0 resection. They are: T4 dMMR ctDNA positivity (provisional) 1/4 #ASCO22

RT @ErikaHamilton9: 40% of Black patients say no one mentioned clinical trials to them. >90% say they want information on trials. This is…

RT @marklewismd: @pashtoonkasi @ASCO @OncoAlert @ryanhuey @gabe_a_brooks @Jcj84Jeremy @mdmanishshah @BenWestphalen @AndreaCercek @anup_kasi…

You know it’s big news when my mom in Ohio called me about this study. Congratulations to @AndreaCercek and team for a huge result for the benefit of our patients #ASCO22

Andrea Cercek @AndreaCercek

Very proud of our study published in @NEJM. 100% clinical complete response with dostarlimab alone in mismatch repair-deficient locally advanced #RectalCancer. No radiation or surgery! @ASCO #ASCO22 @MSKCancerCenter https://t.co/sZypoHBtj7

Outstanding discussion by Dr. Cremolini of #mCRC PARADIGM trial. Do you agree with her treatment algorithm of FOLFOXIRI-bev for pts with KRAS-MT left-sided tumors? #ASCO2022 https://t.co/WGjCz3Nc5E

Tonight, I’m seeing @HAIMtheband in downtown Chicago! Tomorrow, looking forward to seeing old friends and new data at #ASCO22 https://t.co/6EHGH8HRhh

RT @fumikochino: So proud of Dr ⁦@NarjustDumaMD⁩’s well earned place on this ⁦@TheCancerLetter⁩ timeline on the evolution of @ASCO annual m…

I cannot say enough about how proud I am of @fumikochino!! Then add @familyreach into the mix, and I’m swooning. #ASCO22

Family Reach @familyreach

👏 Huge congrats to @fumikochino for winning the Excellence in Equity Award from @ASCO! We're honored to be in the fight against #financialtoxicity alongside changemakers like you. #ASCO22 #healthequity https://t.co/TgrjPYADYH

Fun @TheCancerLetter article on memories from 57yrs of @ASCO (& thx for kind words, @fumikochino!) #MyFirstASCO: I was a resident standing by a lonely HSR poster, watching in awe as Jane Weeks presented, wondering if I’d ever get to do that! #ASCO22 https://t.co/xUjQdb0xyS

US spends more on cancer than any other country--by far. But cancer mortality? Just below median   We're missing something (emphasis on costly Rx & not on prevention/Dx?). Let's keep this in mind at #ASCO22   Great work by @cpgYALE @YaleCOPPER https://t.co/A6PouvRWuE https://t.co/bKgQQj8Uoe

RT @aaronecarroll: It should go without saying, but it evidently can’t be said enough: good science communication matters. We are failing…

RT @RyanNipp: Your Money or Your Life — The High Cost of #Cancer Drugs under Medicare Part D. https://t.co/MIcXuA3o8F @NEJM @DusetzinaS…

Getting to the source of inequity in healthcare means getting to the source of inequity in society. This is a good start. https://t.co/aZJ5Z11KA2